“This form of the drug was registered only for the treatment of adult patients with chronic lymphocytic leukemia, but it was never imported into the territory of the Russian Federation due to its lack of demand,” the pharmaceutical company explained.
The deregistration of MabThera (a solution for subcutaneous administration in a dose of 1600 mg) will not have a negative impact on Russian patients with chronic lymphocytic leukemia, since this drug was not imported and, consequently, not used for the therapy. manufacturer’s notes.
Roche continues to supply MabThera (rituximab) in two forms, a 1400 mg subcutaneous solution and a concentrate for infusion, which is also used to treat patients with chronic lymphocytic leukemia. “The supply of the drug for the treatment of patients with appropriate indications is carried out in the volume provided according to their needs,” the company highlights.
